Today,
Receiving the FDA 510(k) clearance for Vasoview Hemopro
"EVH is a therapy significantly helping patients towards faster recovery by minimizing surgical trauma and reducing post-operative pain. By offering solutions together with extensive training, we aim to continue help facilitating the widespread adoption of this essential therapy. The new generation of Vasoview - Hemopro 3 - symbolizes our dedication to elevating healthcare standards together with our customers," says Elin Frostehav, President Acute Care Therapies at
The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable.
Investor Relations:
Phone: +46 10 335 0043
Email: lars.mattsson@getinge.com
Media contact:
Caroline Örmgård, Head of Public & Media Relations
Phone: +46 10 335 0041
Email: caroline.ormgard@getinge.com
About
With a firm belief that every person and community should have access to the best possible care,
https://news.cision.com/getinge/r/getinge-takes-a-leap-forward-in-cardiovascular-surgery-with-the-510-k--clearance-for-vasoview-hemopr,c3943030
https://mb.cision.com/Main/942/3943030/2657352.pdf
https://news.cision.com/getinge/i/vasoview-hemopro-3-1200x628,c3276440
(c) 2024 Cision. All rights reserved., source